Synthesis and biological activity evaluation of 3-(hetero) arylideneindolin-2-ones as potential c-Src inhibitors-Reference-Cited by-同舟云学术

Synthesis and biological activity evaluation of 3-(hetero) arylideneindolin-2-ones as potential c-Src inhibitors

Published:2022-09-01 Issue:1 Volume:37 Page:2382-2394
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

Princiotto Salvatore¹,Musso Loana¹,Manetti Fabrizio²,Marcellini Valentina²,Maga Giovanni³,Crespan Emmanuele³,Perini Cecilia³,Zaffaroni Nadia⁴,Beretta Giovanni Luca⁴,Dallavalle Sabrina¹^ORCID

Affiliation:

1. Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy

2. Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, Siena, Italy

3. Institute of Molecular Genetics IGM, CNR “Luigi Luca Cavalli-Sforza”, Pavia, Italy

4. Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Funder

Italian MIUR

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2022.2117317

Reference50 articles.

1. Src family kinases, key regulators of signal transduction

2. Regulation, substrates and functions of src

3. The interplay between Src and integrins in normal and tumor biology

4. Amino-terminal basic residues of Src mediate membrane binding through electrostatic interaction with acidic phospholipids.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities;Bioorganic Chemistry;2024-01

2. Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure‐Activity Relationship;Chemistry & Biodiversity;2023-09

3. Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study;Breast Cancer Research and Treatment;2023-03-02

4. Dual activity of indolin-2-ones containing an arylidene motif: DNA and BSA interaction;RSC Advances;2023

5. The potent role of Src kinase-regulating glucose metabolism in cancer;Biochemical Pharmacology;2022-12